My watch list

Apixaban


Apixaban
Systematic (IUPAC) name
1-(4-methoxyphenyl)-7-oxo-6-[4- (2-oxopiperidin-1-yl)phenyl]-4,5- dihydropyrazolo[5,4-c]pyridine- 3-carboxamide
Identifiers
CAS number	503612-47-3
ATC code	?
PubChem	10182969
Chemical data
Formula	C₂₅H₂₅N₅O₄
Mol. mass	459.497
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	oral

Apixaban (manufacturer's designation BMS-562247-01) is a compound being investigated as an anticoagulant. It acts by inhibiting coagulation factor Xa. It is presently undergoing phase III trials in the prevention of venous thromboembolism, together with a number of related competing compounds, such as rivaroxaban.^[1] It is being marketed in a joint venture by Pfizer and Bristol-Myers-Squibb.^[2]

Additional recommended knowledge

Weighing the right way

What is the Correct Way to Check Repeatability in Balances?

Daily Sensitivity Test

A 2007 trial showed that apixaban was equivalent to enoxaparin/open-label heparin in preventing thrombosis is patients who had undergone a knee replacement.^[3]

References

^ Turpie AG (2007). "Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases". Arterioscler. Thromb. Vasc. Biol. 27 (6): 1238-47. doi:10.1161/ATVBAHA.107.139402. PMID 17379841.
^ Bristol-Myers Squibb News Release 26 April 2007. Retrieved on 2007-09-15.
^ Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D (2007). "The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement". J. Thromb. Haemost. 5 (12): 2368–75. doi:10.1111/j.1538-7836.2007.02764.x. PMID 17868430.